Insights from Indian Pediatricians on H2 Receptor Antagonists for Treating Neonates and Infants with Gastrointestinal Disorders

Gastrointestinal Conditions in Neonates and Infants

Common GI Conditions

Gastrointestinal (GI) disorders frequently affect neonates and infants, with several key conditions to consider:

– Gastroesophageal Reflux (GER)
– Gastroesophageal Reflux Disease (GERD)

In addition to these, stress-related gastrointestinal injuries and upper GI bleeding pose significant risks, particularly for infants in intensive care units (ICUs). Prompt intervention is crucial, emphasizing the need for gastric acid-reducing medications (ARMs), especially H2 receptor antagonists (H2RAs), in pediatric gastroenterology.

Understanding GER and GERD

Gastroesophageal Reflux (GER)

GER is a common and typically self-limiting condition in infants, presenting symptoms that may include:

– Regurgitation
– Vomiting
– Coughing
– Choking
– Hiccups
– Irritability

Most infants experience resolution of GER naturally by 6 to 12 months of age.

Gastroesophageal Reflux Disease (GERD)

GERD represents a more serious form of reflux, often challenging to differentiate from GER due to overlapping symptoms. For infants diagnosed with GERD who do not respond to non-pharmacological treatments, ARMs, including H2RAs, are deemed safe and effective for acid suppression.

Stress Ulcer Prevention in Intensive Care

Preventing stress ulcers is essential for infants admitted to ICUs. Stress-related gastrointestinal injuries and upper GI bleeding can arise within the first 48 hours of ICU stay. To reduce these risks, healthcare providers often utilize proton pump inhibitors (PPIs) and H2RAs, such as ranitidine.

Risks Associated with PPIs

Although PPIs are routinely prescribed for stress ulcer prevention, their use is linked to an increased risk of pneumonia in infants. Research suggests that H2RAs, like ranitidine, provide an effective and safer alternative, helping to prevent stress-induced gastric lesions and upper GI bleeding in critically ill neonates, particularly those requiring mechanical ventilation, without elevating pneumonia risk.

Recommendations for ARM Use

Importance of Clear Guidelines

Despite the critical role of ARMs, especially H2RAs, in managing GI conditions in neonates and infants, there is a pressing need for well-defined, practice-based prescribing guidelines. A panel of 24 pediatric specialists from India has formulated comprehensive recommendations on ARM use, published in the May 2025 issue of *Cureus*.

Key Recommendations for H2RAs

The following guidelines are advised for the application of H2RAs in addressing gastrointestinal issues among neonates and infants:

1. ARMs are effective in preventing stress ulcers in critically ill children, particularly those on mechanical ventilation.
2. Assess the necessity for stress ulcer prophylaxis (SUP) for NICU/PICU patients based on clinical factors, including coagulopathy and mechanical ventilation.
3. Utilize ARMs for upper GI bleeds unrelated to Vitamin K deficiency.
4. Consider ARMs for symptomatic reflux that may manifest as irritability, arching, disease progression, or failure to thrive.
5. Avoid using ARM treatment solely based on apnea.
6. Prefer H2RAs (ranitidine, famotidine) over PPIs for SUP in critically ill NICU patients.

Expert Opinions on H2RAs

Dr. Lalit Bharadia, a Consultant Pediatric Gastroenterologist at Neoclinic Children Hospital in Jaipur, remarked, “In cases of acute illness requiring prompt action where the condition is not severe, I prefer using an H2 receptor blocker over a proton pump inhibitor.”

Dr. Sreenath Manikanti from the Department of Neonatology at Kauvery Hospital in Bangalore stated, “H2RAs are effective since proton pump inhibitors are not recommended for neonates due to the risk of necrotizing enterocolitis and fungal infections. H₂ receptor antagonists play a crucial role in preventing stress ulcers, especially in intensive care settings.”

Dr. Gautam Mittal from Gautam Child and Gastro Care in Patiala highlighted the benefits of H2RAs, noting, “PPIs are not indicated for children under one year of age due to the risk of acute kidney injury. H₂RAs have a quicker onset of action and do not carry the same long-term risks associated with PPIs.”

Conclusion

This analysis emphasizes the significance of individualized assessments, prioritizing non-pharmacological interventions, and the prudent use of ARMs. H2RAs, such as ranitidine, may offer a safer alternative to PPIs for managing gastrointestinal conditions in neonates and infants.